Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

Basit Öğe Kaydı
dc.contributor.authorKabacam, Gokhan
dc.contributor.authorDalekos, George N.
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorZachou, Kalliopi
dc.contributor.authorBock, Thomas
dc.contributor.authorErhardt, Andreas
dc.contributor.authorZeuzem, Stefan
dc.date.accessioned2024-04-24T17:24:37Z
dc.date.available2024-04-24T17:24:37Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks of pegylated interferon alpha-2a (180 mu g weekly) with or without adefouir (10 mg daily) in patients with chronic delta hepatitis-induced advanced liver disease and in those with non-advanced liver disease. Materials and Methods: Thirty-one patients with advanced and 27 patients with non-advanced liver disease were assessed. Patients were considered to have advanced liver disease when biopsy disclosed a fibrosis score of >= 4 according to Ishak or when imaging studies were indicative of cirrhosis. Virologic response, defined as achievement of undetectable hepatitis D virus RNA, was assessed at the end of treatment and end of 24 weeks of treatment-free follow-up. Results: Patients with advanced disease had lower hepatitis D virus RNA levels and platelet counts (p=0.014 and p=0.0015, respectively). End of treatment and end of follow-up virologic responses in patients with advanced vs. non-advanced liver disease were similar (29% vs. 19% and 32% vs 23%). Proportion of adverse events did not differ between groups except that thrombocytopenia was noted more often in the advanced liver disease group. Further, four cases of clinically important adverse events including two cases of hepatic decompensation and one case of tuberculosis reactivation occurred in the advanced liver disease group. Conclusions: Pegylated interferon is as effective in patients with advanced liver disease due to chronic delta hepatitis as in patients with non-advanced liver disease, but patients should be monitored closely for clinically important side effects.en_US
dc.description.sponsorshipF. Hoffmann-La Roche; Gilead Sciencesen_US
dc.description.sponsorshipThe trial received financial support from F. Hoffmann-La Roche and Gilead Sciences, who approved the study design as proposed by the investigators.en_US
dc.identifier.doi10.4318/tjg.2012.0538
dc.identifier.endpage568en_US
dc.identifier.issn2148-5607
dc.identifier.issue5en_US
dc.identifier.pmid23161302
dc.identifier.startpage560en_US
dc.identifier.trdizinid140929
dc.identifier.urihttps://doi.org/10.4318/tjg.2012.0538
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/140929
dc.identifier.urihttps://hdl.handle.net/11468/19760
dc.identifier.volume23en_US
dc.identifier.wosWOS:000311871900020
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCirrhosisen_US
dc.subjectHepatitis Deltaen_US
dc.subjectPegylated Interferonen_US
dc.subjectTherapyen_US
dc.titlePegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitisen_US
dc.titlePegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu